PLUS THERAPEUTICS, INC. (PSTV) - Dilution Analysis

10-Q filing | 6.6M shares outstanding

S-1 filing: This S-1 filing outlines a firm commitment underwritten offering of units and pre-funded units, each consisting of common stock or pre-funded warrants and warrants, aiming to raise capital for working capital and general corporate purposes.

10-Q filing | 137.4M shares outstanding

10-Q filing | 99.3M shares outstanding

S-1 filing: This prospectus relates to the offer and sale of up to 33,000,000 shares of our common stock by Lincoln Park Capital Fund, LLC, subject to certain limitations described in this prospectus.

S-1/A filing: This prospectus relates to the offer and sale of up to 17,000,000 shares of our common stock by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder.

S-1 filing: This prospectus relates to the offer and sale of up to 17,000,000 shares of our common stock by Lincoln Park Capital Fund, LLC, with potential gross proceeds of up to $50 million to the company.

10-Q filing | 32.7M shares outstanding

8-K filing: Plus Therapeutics, Inc. increased the authorized shares of common stock from 100,000,000 to 2,000,000,000 and the stockholders approved the extension of the term of the Company's May 2024 Warrants.

S-3/A filing: This prospectus relates to up to an aggregate of 1,565,044,860 shares of common stock of Plus Therapeutics, Inc., which may be offered for sale from time to time by selling stockholders named herein.

POS AM filing: This prospectus relates to the offer and sale from time to time by selling stockholders named herein of up to an aggregate of 3,248,878 shares of common stock of Plus Therapeutics, Inc.

S-3 filing: This prospectus relates to the resale of common stock and warrants by selling stockholders.

10-K filing | 17.0M shares outstanding

10-Q filing | 5.9M shares outstanding

S-3 filing: The company may offer and sell up to $100,000,000 in aggregate initial offering price of common stock, preferred stock, debt securities, depositary shares, stock purchase contracts and subscription rights from time to time in one or more offerings.

10-Q filing | 5.9M shares outstanding

S-1/A filing: This prospectus relates to the resale of up to an aggregate of 10,774,596 shares of common stock by selling stockholders.

S-1 filing: This S-1 filing relates to the registration of up to 10,774,596 shares of common stock offered by selling stockholders of Plus Therapeutics, Inc.

10-Q filing | 4.3M shares outstanding

S-1/A filing: The company is offering common stock together with warrants, and pre-funded warrants, for working capital and general corporate purposes.

10-K filing | 4.3M shares outstanding

S-1 filing: The company is filing an S-1 to offer common stock and pre-funded warrants.

S-1 filing: This prospectus relates to the offer and sale of up to 1,300,000 shares of our common stock by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder.

10-Q filing | 4.5M shares outstanding

10-Q filing | 2.9M shares outstanding

S-1 filing: This S-1 filing relates to the offer and sale of up to 1,500,000 shares of common stock by Lincoln Park Capital Fund, LLC, with the company potentially receiving up to $50.0 million in gross proceeds from sales of common stock to Lincoln Park under a purchase agreement.

10-Q filing | 34.8M shares outstanding

10-K filing | 35.1M shares outstanding

10-Q filing | 33.6M shares outstanding

S-1 filing: This S-1 filing relates to the offer and sale of up to 9,500,000 shares of common stock by Lincoln Park Capital Fund, LLC. The company may receive up to $50.0 million aggregate gross proceeds from sales of common stock to Lincoln Park under a purchase agreement.

10-Q filing | 22.3M shares outstanding

10-Q filing | 22.2M shares outstanding

10-K filing | 22.2M shares outstanding

10-Q filing | 15.4M shares outstanding

S-1 filing: This S-1 filing relates to the offer and sale of up to 5,865,000 shares of common stock by Lincoln Park Capital Fund, LLC, with the company potentially receiving up to $25.0 million aggregate gross proceeds under the Purchase Agreement.

10-Q filing | 12.1M shares outstanding

10-Q filing | 21.1M shares outstanding

S-1 filing: This prospectus relates to the offer and sale of up to 4,500,000 shares of our common stock by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder.

10-K filing | 21.1M shares outstanding

S-1 filing: This prospectus relates to the offer and sale of up to 1,519,000 shares of our common stock by Lincoln Park Capital Fund, LLC.

10-Q filing | 4.8M shares outstanding

S-3 filing: Plus Therapeutics, Inc. files an S-3 registration statement to offer and sell debt securities, common stock, preferred stock, depositary shares, warrants and rights with an aggregate initial offering price not to exceed $100,000,000.

8-K filing: Plus Therapeutics, Inc. entered into a purchase agreement with Lincoln Park Capital Fund, LLC, for the sale of up to $25 million of the Company's common stock and issued 180,701 commitment shares to Lincoln Park.

8-K filing: Plus Therapeutics, Inc. amended the terms of underwriter warrants issued to H.C. Wainwright & Co., LLC, modifying cash payment obligations and establishing a new exercise price of $2.81 per share.

10-Q filing | 4.3M shares outstanding

8-K filing: Plus Therapeutics, Inc. amended the terms of Series U warrants with certain holders, including establishing an exercise price of $2.25.

10-Q filing | 4.1M shares outstanding

10-K filing | 3.9M shares outstanding